Archit Devarajan

30 posts

Archit Devarajan

Archit Devarajan

@ArchitDevarajan

Doctoral Student @NYUniversity | BS-MS (Bio.) @iiserbhopal ('18-'23) | iGEM '20, '21

Mumbai, India Katılım Aralık 2016
152 Takip Edilen68 Takipçiler
Archit Devarajan
Archit Devarajan@ArchitDevarajan·
Heartiest Congratulations @KamatLab_IISER!!! Extremely proud to be a lab alumnus!!
Infosys Prize@InfosysPrize

#InfosysPrize2024 in Life Sciences is awarded to Prof. Siddhesh Kamat, @KamatLab_IISER, of @IISERPune for his discoveries concerning bioactive lipids and their receptors, and their metabolic and signaling pathways. His research using advanced methods to understand the function of lipids, a key component of cells, has important implications for understanding the role of these molecules in a range of cellular functions and human diseases.

English
0
0
4
224
Archit Devarajan retweetledi
Sigma-Aldrich
Sigma-Aldrich@SigmaAldrich·
It’s just a tiny bottle.. It probably doesn’t smell that bad Tiny Bottle:
Sigma-Aldrich tweet media
English
76
267
2.1K
222.3K
Archit Devarajan retweetledi
Siddhesh Kamat
Siddhesh Kamat@KamatLab_IISER·
Today was @ArchitDevarajan & @ChaitanyaKatka4’s last day in lab @IISERPune. Both have been wonderful & very productive researchers over the past year & now move on to their PhD’s. Looking forward to exciting science from them. (Pic from their farewell lunch today).
Siddhesh Kamat tweet media
English
0
3
72
3.4K
Archit Devarajan retweetledi
Wei Zhao
Wei Zhao@zhaoweiasu·
In vivo base editing works in humans! Congratulations to @KomorLab, @NicoleGaudelli, and @davidrliu for advancing gene editing science and inventing base editing technology! Great work by both the @BeamTx team and the Verve team to make it happen! @skathire and @ambellinger 👏🎉
Wei Zhao tweet mediaWei Zhao tweet media
English
4
18
129
51.3K
Archit Devarajan retweetledi
David R. Liu
David R. Liu@davidrliu·
In a major milestone for science, for medicine, and for patients, the world’s first CRISPR drug has been approved in the UK. “A new treatment for sickle-cell disease and transfusion-dependent β-thalassemia has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) for patients aged 12 and over after a rigorous assessment of its safety, quality and effectiveness.” Congratulations to the many scientists, doctors, patients, and industry leaders who made this development possible.🍻 gov.uk/government/new…
English
21
308
1.4K
189.1K